上海市广发律师事务所 关于上海凯利泰医疗科技股份有限公司 2025 年第二次临时股东大会的法律意见书 致：上海凯利泰医疗科技股份有限公司 上海凯利泰医疗科技股份有限公司（以下简称"公司"）2025 年第二次临时 股东大会于 2025 年 8 月 28 日在上海市浦东新区凯庆路 299 号东江明城大酒店副 楼（东江苑运动城）五楼东江 A 厅召开。上海市广发律师事务所经公司聘请， 委派律师成赟、陈雨兰律师出席现场会议，根据《中华人民共和国公司法》（以 下简称"《公司法》"）、《上市公司股东会规则》（以下简称"《股东会规则》"）等 法律法规、其他规范性文件以及《上海凯利泰医疗科技股份有限公司章程》（以 下简称"《公司章程》"）的规定，就本次股东大会的召集和召开程序、召集人及 出席会议人员的资格、会议议案、表决方式和表决程序、表决结果和会议决议等 出具本法律意见书。 为出具本法律意见书，本所律师对本次股东大会所涉及的有关事项进行了审 查，查阅了相关会议文件，并对有关问题进行了必要的核查和验证。 公司已向本所保证和承诺，公司向本所律师所提供的文件和所作的陈述和说 明是完整的、真实的和有效的，有关原件及其上面的签字和印章 ...

证券代码：300326 证券简称：凯利泰 公告编号：2025-092 上海凯利泰医疗科技股份有限公司 2025年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会没有出现否决议案的情形； 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、 会议召开和出席情况 （一）会议召开情况 1、会议的召集人：公司董事会 2、会议时间及地点： 现场会议召开时间为：2025 年 8 月 28 日（星期四）14 时 50 分，会议地点为：上 海市浦东新区凯庆路 299 号东江明城大酒店副楼（东江苑运动城）五楼东江 A 厅。 网络投票时间为：2025 年 8 月 28 日，其中，通过深圳证券交易所交易系统进行网 络投票的具体时间为：2025年 8月 28 日上午9:15—9:25，9:30—11:30，下午 13:00—15:00； 通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 8 月 28 日上午 9:15 至 下午 15:00。 3、会议召开方式：本次股东大会采取现场投票、网络投票相结合的方式进行 ...

Core Viewpoint - ST凯利 reported a year-on-year increase in both revenue and net profit for the 2025 mid-year report, indicating a positive growth trend despite some declines in profitability ratios [1] Financial Performance - The total operating revenue for the 2025 mid-year report reached 546 million yuan, a year-on-year increase of 14.75% [1] - The net profit attributable to shareholders was 43.81 million yuan, reflecting a year-on-year increase of 44.88% [1] - In the second quarter, the operating revenue was 281 million yuan, up 22.46% year-on-year, while the net profit attributable to shareholders was 22.05 million yuan, an increase of 13.9% [1] Profitability Metrics - The gross profit margin was 50.59%, a decrease of 0.78% year-on-year [1] - The net profit margin stood at 8.11%, down 5.95% compared to the previous year [1] - Total sales, management, and financial expenses amounted to 197 million yuan, accounting for 36.07% of revenue, which is an increase of 6.03% year-on-year [1] Shareholder Metrics - The earnings per share (EPS) was 0.06 yuan, representing a year-on-year increase of 44.79% [1] - The operating cash flow per share was 0.06 yuan, up 38.68% year-on-year [1] - The net asset value per share was 3.86 yuan, a decrease of 4.43% year-on-year [1] Debt and Asset Management - The company reported a significant increase in interest-bearing liabilities, which rose by 79.97% to 255 million yuan [1] - Cash and cash equivalents decreased by 30.59% to 286 million yuan [1] - Accounts receivable decreased by 19.12% to 195 million yuan [1] Business Model and Historical Performance - The company's business model relies heavily on marketing-driven performance, which requires further investigation into the underlying drivers [2] - Historical data indicates a median Return on Invested Capital (ROIC) of 7.43% over the past decade, with a notably poor performance in 2020, where ROIC was -3.6% [1]

Core Viewpoint - Shanghai Kelly Tai Medical Technology Co., Ltd. announced a correction regarding the sale of equity in Jianuo Medical Management Group Co., Ltd. and the reduction of capital to exit Shanghai Jingzheng Medical Technology Co., Ltd. [1] Financial Data Correction - The financial data for Jingzheng Medical for the most recent year and period has been corrected as follows: - Total assets as of December 31, 2024: 502.77 million (audited) and as of May 31, 2025: 531.57 million (unaudited) [2] - Total liabilities as of December 31, 2024: 302.51 million (audited) and as of May 31, 2025: 312.74 million (unaudited) [2] - Net assets as of December 31, 2024: 200.26 million (audited) and as of May 31, 2025: 218.83 million (unaudited) [2] - Total receivables as of December 31, 2024: 96.72 million (audited) and as of May 31, 2025: 94.77 million (unaudited) [2] Company Commitment - The company expressed its commitment to improving the quality of information disclosure and will enhance the verification process for future disclosures [2][3]

证券代码：300326 证券简称：ST凯利 公告编号：2025-091 上海凯利泰医疗科技股份有限公司 关于出售洁诺医疗管理集团有限公司股权 并减资退出上海景正医疗科技有限公司的更正公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 上海凯利泰医疗科技股份有限公司（以下简称"公司"）于2025年8月5日 在巨潮资讯网上披露了《关于出售洁诺医疗管理集团有限公司股权并减资退出 上海景正医疗科技有限公司的公告》（公告编号：2025-075）。由于工作人员 疏忽，原公告中部分信息有误，现对相关内容进行更正： 更正前： 景正医疗最近一年及一期的主要财务数据如下： 单位：万元 | 项目 | 2024年12月31日 | 2025年5月31日 | | --- | --- | --- | | | （经审计） | （未经审计） | | 资产总额 | 50,277.33 | 68,493.40 | | 负债总额 | 30,251.06 | 31,273.52 | | 净资产 | 20,026.27 | 37,219.88 | | 应收款项总额 | 9,671.55 | 9,477 ...

证券代码：300326 证券简称：ST凯利 公告编号：2025-090 上海凯利泰医疗科技股份有限公司 关于召开2025年第二次临时股东大会的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、召开本次会议的基本情况 1、股东大会届次：2025年第二次临时股东大会 2、会议召集人：公司董事会 3、会议召开的合法性及合规性：公司第六届董事会第九次会议审议通过了 《关于提请召开公司2025年第二次临时股东大会的议案》，本次股东大会会议的召 开符合有关法律、行政法规、部门规章、规范性文件和公司章程等规定。 4、会议召开日期和时间： （1）现场会议时间为：2025年8月28日（星期四）14时50分 （2）网络投票时间：2025年8月28日。其中，通过深圳证券交易所交易系统 进行网络投票的时间为：2025年8月28日上午9:15—9:25、9:30—11:30，下午 13:00—15:00；通过深圳证券交易所互联网投票系统投票的时间为：2025年8月28 日上午9:15至下午15:00。 5、会议召开方式： 本次股东大会采用现场投票、网络投票相结合的方式召开 ...

Core Insights - ST Kelly (300326) reported a revenue of 546 million yuan for the first half of 2025, representing a year-on-year increase of 14.75% [1] - The net profit attributable to shareholders reached 43.81 million yuan, showing a significant year-on-year growth of 44.88% [1] Revenue Growth - The increase in revenue is primarily driven by the growth in the vertebroplasty business segment and an increase in trade business income [1] - Revenue from minimally invasive vertebroplasty products amounted to 165 million yuan, reflecting a year-on-year growth of 11.54% [1] Business Strategy - The company focuses on innovation in orthopedic products, exploring new materials, fields, and technologies based on market trends and clinical feedback [1] - ST Kelly is committed to enhancing production efficiency, process innovation, and expanding production scale to reduce production costs [1] - The company continues to strengthen cost control and expense management by compressing labor costs and lowering operating expenses [1] Product and Service Overview - ST Kelly's main business involves the production, research and development, sales, and service of orthopedic implant medical devices, including spinal minimally invasive products and orthopedic trauma implant devices [1] - The wholly-owned subsidiary Elliquence specializes in the research, production, and sales of surgical energy platforms and high-value consumables [1] - The holding subsidiary Jeno Medical provides professional cleaning and sterilization solutions for medical devices, equipment, and healthcare materials [1]

Group 1 - The board of directors of Shanghai Kellytech Medical Technology Co., Ltd. held its tenth meeting of the sixth session on August 19, 2025, with all seven directors present, confirming compliance with relevant laws and regulations [1] - The board approved the 2025 semi-annual report, affirming that it accurately reflects the company's actual situation without any false records or misleading statements [1][2] - The board authorized management to conduct daily related transactions within a projected amount not exceeding 30.55 million yuan (excluding tax) for the year 2025, with a comparison to the previous year's actual transactions [2][3] Group 2 - The expected amount for daily related transactions in 2025 is lower than the actual amount of 43.3 million yuan in 2024, which was 28.77 million yuan, excluding transactions with a related party controlled by a former director [2] - The board's decision regarding the excess portion of related transactions from 2024 was also approved, with a total excess of 3.2441 million yuan noted [3] - The independent directors reviewed and approved the related transaction proposals, ensuring transparency and compliance with regulations [3]

Core Viewpoint - Shanghai Kinetic Medical Co., Ltd. reported a 14.75% increase in revenue for the first half of 2025 compared to the same period in 2024, driven by growth in its vertebroplasty business and trade operations [6][22]. Company Overview and Financial Indicators - The company, listed as ST Kinetic with stock code 300326, operates primarily in the orthopedic implant medical device sector, focusing on the production, research, and sales of spinal minimally invasive products and orthopedic trauma implants [5][6]. - The total assets at the end of the reporting period were approximately CNY 3.35 billion, showing no significant change from the previous year [6]. Business Operations - The company specializes in vertebroplasty systems used for treating osteoporotic vertebral compression fractures, including percutaneous vertebroplasty (PVP) and percutaneous balloon kyphoplasty (PKP) systems [7][8]. - The company has established a joint venture with TECRES S.P.A. to develop and produce bone cement products, enhancing its product line in the orthopedic sector [9][19]. Financial Performance - Revenue for the reporting period was CNY 546.1 million, up from CNY 475.9 million in the previous year, with a corresponding increase in net profit attributable to shareholders of CNY 33.77 million, a 35.47% rise [6][22]. - Operating costs increased by 15.68% to CNY 269.83 million, primarily due to higher sales volume [22]. - The company reported a net cash flow from operating activities of CNY 65.62 million, reflecting a 38.68% increase compared to the previous year [22]. Strategic Developments - The company is focusing on optimizing its business model and resource allocation, particularly in response to the implementation of centralized procurement policies in the orthopedic sector [14][20]. - Recent acquisitions, including that of Elliquence, LLC, are aimed at expanding the company's product offerings and market reach in the orthopedic device field [11][18]. Market Position and Competitive Advantage - The company holds a leading market share in the vertebroplasty segment in China, benefiting from a strong brand reputation and established relationships with hospitals and distributors [20]. - Continuous investment in R&D and quality management has positioned the company favorably within the industry, allowing it to maintain a competitive edge [21].

Core Viewpoint - Shanghai Kelly Medical Technology Co., Ltd. reported a significant increase in revenue and net profit for the first half of 2025, indicating strong operational performance and growth potential in the medical technology sector [1][2]. Financial Performance - The company's operating income for the reporting period reached approximately 546.1 million yuan, representing a 14.75% increase compared to 475.9 million yuan in the same period last year [1]. - Net profit attributable to shareholders was approximately 43.8 million yuan, reflecting a 44.88% increase from 30.2 million yuan year-on-year [1]. - The net profit after deducting non-recurring gains and losses was about 45.1 million yuan, up 38.68% from 32.5 million yuan in the previous year [1]. - Basic earnings per share were reported at 0.0422 yuan, a decrease of 44.79% compared to 0.0611 yuan from the previous year [1]. Financial Position - Total assets at the end of the reporting period were approximately 3.35 billion yuan, showing a slight increase from 3.35 billion yuan at the end of the previous year [2]. - The net assets attributable to shareholders were approximately 2.77 billion yuan, up 1.68% from 2.72 billion yuan [2]. Shareholder Information - The top ten shareholders include various domestic investment companies, with the largest shareholder holding 6.99% of the shares [2][4]. - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period [5].